I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 97-100

  Barker, A D ^a   Sigman, C C ^b   Kelloff, G J ^a   Hylton, N M ^c   Berry, D A ^d   Esserman, L J ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 67650652432     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.68     Document Type: Review

References (15)

1. Valero, V.V., Buzdar, A.U. & Hortobagyi, G.N. Locally advanced breast cancer. Oncologist 1, 8-17 (1996).
2. Newman, L.A. & Mamounas, E.P. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surg. Clin. North Am. 87, 279-305, vii (2007).
3. DiMasi, J., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development cost. J. Health Econ. 22, 151-185 (2003).
4. Loi, S., Buyse, M., Sotiriou, C. & Cardoso, F. Challenges in breast cancer clinical trial design in the postgenomic era. Curr. Opin. Oncol. 16, 536-541 (2004).
5. Albertson, D. et al. Genomic approaches to breast cancer subset identifcation and treatment. San Antonio Breast Cancer Symp., San Antonio, TX, 13-16 December 2007. Abstr 31.
6. Gomez, R. et al. Preliminary results from I-SPY trial: tumor patterns on pre-treatment MRI predict breast conservation therapy eligibility. San Antonio Breast Cancer Symp., San Antonio, TX, 13-16 December 2007. Abstr 2024.
7. Hylton, N. et al. Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial. San Antonio Breast Cancer Symp., San Antonio, TX, 13-16 December 2007. Abstr 80.
8. Esserman, L.J., van't Veer, L.J., Perou, C., Rutgers, E.J. & Davis, S.E. Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention. San Antonio Breast Cancer Symp., San Antonio, TX, 10-14 December 2008. Abstr 6034.
9. Gomez, R.E. et al. Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). San Antonio Breast Cancer Symp., San Antonio, TX, 10-14 December 2008. Abstr 202.
10. Berry, D.A. Bayesian clinical trials. Nat. Rev. Drug Discov. 5, 27-36 (2006).
11. Mook, S., Van't Veer, L.J., Rutgers, E.J., Piccart-Gebhart, M.J. & Cardoso, F. Individualization of therapy using MammaPrint: from development to the MINDACT Trial. Cancer Genomics Proteomics 4, 147-155 (2007).
12. Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S. & Piccart-Gebhart, M.J. Clinical application of the 70-gene profle: the MINDACT trial. J. Clin. Oncol. 26, 729-735 (2008).
13. Nijdam, A.J. et al. Physicochemically modifed silicon as a substrate for protein microarrays. Biomaterials 28, 550-558 (2007).
14. Hylton, N., Blume, J., Bernreuter, W., Pisano, E., Rosen, M. & Morris, E. MRI assessment of breast cancer response to neoadjuvant chemotherapy: preliminary fndings of the American College of Radiology Imaging Network (ACRIN) Trial 6657. Radiological Society of North America, Chicago, IL, 2008. Abstr SSA0101.
15. Hylton, N.M. et al. Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary fndings of the American College of Radiology Imaging Network (ACRIN) trial 6657. San Antonio Breast Cancer Symp., San Antonio, TX, 10-14 December 2008. Abstr 6043.